BACKGROUND: Platelets and leukocytes may influence each others' function, i.e. platelet-leukocyte cross-talk. Diabetes mellitus (DM) is associated with platelet and leukocyte dysfunction. OBJECTIVE: To evaluate platelet-leukocyte cross-talk, and if this might contribute to platelet and leukocyte dysfunction and microangiopathy in DM patients. PATIENTS AND METHODS: We evaluated platelet and leukocyte function, and cross-talk between these cells in Type 1 DM patients without (n = 19) and with (n = 20) microangiopathy, and healthy subjects (n = 27), using whole blood flow cytometry. Platelet-leukocyte cross-talk was studied in hirudinized whole blood incubated at 37 degrees C with stirring. RESULTS: Basal single platelet P-selectin and leukocyte CD11b expression were similar in DM patients and healthy subjects, whilst circulating platelet-leukocyte aggregates and plasma elastase levels were elevated in DM patients. The thromboxane A2 analog U46619 (3 x 10(-7) m) induced more marked increases of platelet P-selectin expression and platelet-leukocyte aggregation in DM patients than in healthy subjects. The leukocyte-specific agonist N-formyl-methionyl-leucyl-phenylalanine (fMLP) (10(-7) m) induced more marked CD11b expression in DM patients with microangiopathy, compared with healthy subjects. Platelet-leukocyte cross-talk induced by U46619 (10(-6) m) showed no difference between DM patients and healthy subjects. fMLP (10(-6) m) evoked marked leukocyte activation, which subsequently caused mild platelet P-selectin expression. This leukocyte-platelet cross-talk was more pronounced in DM patients than in healthy subjects. Furthermore, enhanced leukocyte-platelet cross-talk was correlated to platelet hyperreactivity among DM patients with microangiopathy only. CONCLUSIONS: Type 1 DM is associated with platelet and leukocyte hyperactivity, and enhanced leukocyte-platelet cross-talk, which may contribute to platelet hyperactivity and the microvascular complications seen in Type 1 DM.
BACKGROUND: Platelets and leukocytes may influence each others' function, i.e. platelet-leukocyte cross-talk. Diabetes mellitus (DM) is associated with platelet and leukocyte dysfunction. OBJECTIVE: To evaluate platelet-leukocyte cross-talk, and if this might contribute to platelet and leukocyte dysfunction and microangiopathy in DMpatients. PATIENTS AND METHODS: We evaluated platelet and leukocyte function, and cross-talk between these cells in Type 1 DMpatients without (n = 19) and with (n = 20) microangiopathy, and healthy subjects (n = 27), using whole blood flow cytometry. Platelet-leukocyte cross-talk was studied in hirudinized whole blood incubated at 37 degrees C with stirring. RESULTS: Basal single platelet P-selectin and leukocyte CD11b expression were similar in DMpatients and healthy subjects, whilst circulating platelet-leukocyte aggregates and plasma elastase levels were elevated in DMpatients. The thromboxane A2 analog U46619 (3 x 10(-7) m) induced more marked increases of platelet P-selectin expression and platelet-leukocyte aggregation in DMpatients than in healthy subjects. The leukocyte-specific agonist N-formyl-methionyl-leucyl-phenylalanine (fMLP) (10(-7) m) induced more marked CD11b expression in DMpatients with microangiopathy, compared with healthy subjects. Platelet-leukocyte cross-talk induced by U46619 (10(-6) m) showed no difference between DMpatients and healthy subjects. fMLP (10(-6) m) evoked marked leukocyte activation, which subsequently caused mild platelet P-selectin expression. This leukocyte-platelet cross-talk was more pronounced in DMpatients than in healthy subjects. Furthermore, enhanced leukocyte-platelet cross-talk was correlated to platelet hyperreactivity among DMpatients with microangiopathy only. CONCLUSIONS: Type 1 DM is associated with platelet and leukocyte hyperactivity, and enhanced leukocyte-platelet cross-talk, which may contribute to platelet hyperactivity and the microvascular complications seen in Type 1 DM.
Authors: G Sharma; M Boules; S Punchai; A Strong; D Froylich; N H Zubaidah; C O'Rourke; S A Brethauer; J Rodriguez; K El-Hayek; M Kroh Journal: Surg Endosc Date: 2016-08-05 Impact factor: 4.584
Authors: W L Newcomb; J L Polhill; A Y Chen; T S Kuwada; K S Gersin; S B Getz; K W Kercher; B T Heniford Journal: Hernia Date: 2008-05-21 Impact factor: 4.739
Authors: Man K S Lee; Michael J Kraakman; Dragana Dragoljevic; Nordin M J Hanssen; Michelle C Flynn; Annas Al-Sharea; Gopalkrishna Sreejit; Camilla Bertuzzo-Veiga; Olivia D Cooney; Fatima Baig; Elizabeth Morriss; Mark E Cooper; Emma C Josefsson; Benjamin T Kile; Prabhakara R Nagareddy; Andrew J Murphy Journal: Arterioscler Thromb Vasc Biol Date: 2021-01-14 Impact factor: 8.311
Authors: Karthik Balasubramaniam; Girish N Viswanathan; Sally M Marshall; Azfar G Zaman Journal: Cardiol Res Pract Date: 2012-01-05 Impact factor: 1.866